inotuzumab ozogamicin
1 clinical trial
1 product
11 abstracts
5 indications
Indication
Acute Leukemias of Ambiguous LineageIndication
Adult Acute Lymphoblastic LeukemiaIndication
Burkitt lymphomaAbstract
Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib/II study.Org: Autolus Therapeutics, H. Lee Moffitt Cancer Center and Research Institute, The David and Etta Jonas Center for Cellular Therapy, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute,
Abstract
Evolution of tisagenlecleucel use for the treatment of pediatric and young adult relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL): Center for International Blood & Marrow Transplant Research (CIBMTR) registry results.Org: Dana-Farber Cancer Institute, Boston Children's Hospital Cancer and Blood Disorders Center, Memorial Sloan Kettering Cancer Center, University of Colorado Denver, Children's Mercy Hospital,
Clinical trial
S1312, A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination With CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients With Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt's Leukemia)Status: Completed, Estimated PCD: 2022-01-01
Abstract
A phase 3 trial of inotuzumab ozogamicin for high-risk B-ALL: Second safety phase results from Children’s Oncology Group AALL1732.Org: Cincinnati Children's Hospital Medical Center, Children's Hospital of Philadelphia, University of Florida Department of Biostatistics, UCSF Benioff Children's Hospital Oakland, Loyola University Medical Center,
Abstract
Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.Org: University of Chicago, H. Lee Moffitt Cancer Center and Research Institute, City of Hope National Medical Center, University of Washington/Fred Hutchinson Cancer Research Center, University of Colorado Cancer Center,
Abstract
A phase I trial of dose-adjusted EPOCH plus inotuzumab ozogamicin (InO) in adults with relapsed/refractory (R/R) B lymphoblastic leukemia/lymphoma (B-ALL).Org: Fred Hutchinson Cancer Center, University of Washington/Fred Hutchinson Cancer Center,
Abstract
Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703.Org: Alliance Statistics and Data Management Center, Rochester, MN, University of Chicago, Chicago, IL, Georgetown University Hospital, Washington, DC, Helen F. Graham Cancer Center and Research Institute, Newark, DE, University of North Carolina, Chapel Hill, NC,
Abstract
Inotuzumab ozogamicin (INO) for the treatment of measurable residual disease (MRD) in patients with B-cell acute lymphoblastic leukemia (B-ALL): Results from a phase II study.Org: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
A phase II study of hyper-CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)–negative B-cell acute lymphoblastic leukemia (ALL).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Mini-hyper-CVD plus inotuzumab ozogamicin (InO), with or without blinatumomab (Blina), in older patients with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL): Updates from a phase II trial.Org: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Mini-hyper-CVD with venetoclax (Ven) for patients with relapsed/refractory (R/R) Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL): A phase II study.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Product
Inotuzumab ozogamicinAbstract
Phase II trial of mini-hyper-CVD-inotuzumab (InO) followed by blinatumomab (blina) consolidation in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).Org: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, Chao Family Comprehensive Cancer Center, University of California, Irvine, CA,